SCHEMBL31497342

SCHEMBL31497342

CC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(N)=O

nearest known ligand 0.52

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 4/20 0.52
▸ GNPAT O15228 1/20 0.48
▸ BACE1 P56817 4/20 0.47
▸ BACE2 Q9Y5Z0 3/20 0.47
▸ BMP1 P13497 2/20 0.47
▸ SIRT5 Q9NXA8 2/20 0.46
▸ ACE P12821 1/20 0.44
▸ NOD2 Q9HC29 1/20 0.43
▸ YWHAZ P63104 1/20 0.41
▸ TASP1 Q9H6P5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31497402 0.98 PTPN1 (0.51) PTPN1GNPATBACE1BACE2BMP1
SCHEMBL31497323 0.93 PTPN1 (0.48) PTPN1GNPATBACE1BACE2BMP1
SCHEMBL31497330 0.91 BACE1 (0.48) PTPN1BACE1BACE2BMP1SIRT5
SCHEMBL22640930 0.91 PTPN1 (0.47) PTPN1GNPATBACE1BACE2BMP1
SCHEMBL24616825 0.90 PTPN1 (0.50) PTPN1GNPATBACE1BACE2BMP1
SCHEMBL22640920 0.90 PTPN1 (0.50) PTPN1GNPATBACE1BACE2BMP1
SCHEMBL31497334 0.89 ERBB2 (0.49) PTPN1BACE1BACE2BMP1SIRT5
SCHEMBL29517483 0.88 GNPAT (0.53) PTPN1GNPATBACE1BACE2BMP1
SCHEMBL31497337 0.88 ERBB2 (0.50) PTPN1BACE1BACE2SIRT5
SCHEMBL24616797 0.88 SIRT5 (0.47) PTPN1GNPATBACE1BACE2BMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388623-A1 PEPTIDE INHIBITOR AND USE THEREOF CHENGDU BRILLIANT INSPIRATION BIOTHERAPEUTICS CO LTD (CN) 2025-12-25 — — US disclosed
EP-4545551-A1 PEPTIDE INHIBITOR AND USE THEREOF Chengdu Brilliant Inspiration Biotherapeutics Co., Ltd (CN) 2025-04-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388623-A1 PEPTIDE INHIBITOR AND USE THEREOF VIP, TGFB1, FN1 PTPN1 637/4885GNPAT 3401/4885BACE1 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback